Back to Search
Start Over
Current status of CAR-T cells in the treatment of malignant solid tumors.
- Source :
- AIP Conference Proceedings; 12/10/2022, Vol. 2589 Issue 1, p1-9, 9p
- Publication Year :
- 2022
-
Abstract
- The potential of immunotherapy as a treatment method for cancer is obvious based on the significant clinical response of a significant number of patients, mainly to chimeric antigen receptor-expressing pericyte transfer using transgenic autologous T cells. Nevertheless, the vast majority of malignant solid tumors do not respond specifically to CAR-T cell injections such as breast, colon and lung cancers. Suboptimal outcomes have been linked to lower expansion. They are also related to the durability of adoptively transferred CAR-T cells, antigen-negative relapses, and impairment by an immunosuppressive tumor microenvironment in a series of clinical trials. The current status of CAR-T cell therapy of solid cancers is discussed. At the same time, this paper also discusses the barriers and how to overcome these obstacles so that CAR-T immunotherapy can be one of the treatment methods for malignant solid tumors. [ABSTRACT FROM AUTHOR]
- Subjects :
- CANCER cells
T cells
COLON cancer
TUMORS
TUMOR microenvironment
BREAST
ALEMTUZUMAB
Subjects
Details
- Language :
- English
- ISSN :
- 0094243X
- Volume :
- 2589
- Issue :
- 1
- Database :
- Complementary Index
- Journal :
- AIP Conference Proceedings
- Publication Type :
- Conference
- Accession number :
- 160869582
- Full Text :
- https://doi.org/10.1063/5.0111898